Glucagon - Xeris Pharmaceuticals

Drug Profile

Glucagon - Xeris Pharmaceuticals

Alternative Names: G-Pen; G-Pen Jr; G-Pen Mini; Glucagon infusion - Xeris; Injectable stable glucagon - Xeris; Xeris glucagon; XeriSol G-Pump

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XERIS Pharmaceuticals
  • Developer Xeris Pharmaceuticals
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoglycaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypoglycaemia

Most Recent Events

  • 04 Oct 2017 Efficacy data from a phase II trial in Type-1 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 27 Sep 2017 Xeris Pharmaceuticals completes a phase III trial in Hypoglycaemia (In adolescents, In children) in USA (SC) (NCT03091673)
  • 25 Sep 2017 Xeris Pharmaceuticals completes a phase III trial in Hypoglycaemia in Canada and USA (SC) (NCT02656069)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top